regulatory
confidence high
sentiment negative
materiality 0.85
Tempest Therapeutics hit with Nasdaq delisting notice after missing $2.5M equity compliance extension
Tempest Therapeutics, Inc.
- Nov 17, 2026: Nasdaq Staff issued delisting notification, saying Tempest did not meet terms of the extension granted Oct 30, 2026 (deadline Nov 16, 2026).
- Company failed to complete a capital raising transaction needed to regain compliance with Nasdaq Listing Rule 5550(b)(1), the $2.5M minimum stockholders' equity rule.
- Root cause: stockholders' equity below $2.5 million as reported in the Form 10-Q for the quarter ended March 31, 2026; original notice received May 19, 2026.
- Tempest will appeal via a Rule 5815 oral hearing request, which stays suspension/delisting; shares continue trading on the Nasdaq Capital Market meanwhile.
- Hearings typically occur 30-45 days after the request, with a panel decision usually within 30 days; company gives no assurance the appeal succeeds.
Featured in Daily 8-K Digest
Selected #1 for 2026-11-20.
Read digest